序号股东名称持股比例1无锡罗伯迈德医疗科技有限公司100% 经营范围含技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；第一类医疗器械销售； 第二类医疗器械销售；货物进出口；技术进出口；进出口代理。（除依法须经批准的项目外，凭营业执 照依法自主开展经营活动）许可项目：第三类医疗器械经营。（依法须经批准的项目，经相关部门批准 后方可开展经营活动，具体经营项目以相关部门批准文件或许可证件为准） 天眼查App显示，近日，上海灵犀慧启医疗科技有限责任公司成立，法定代表人为李世英，注册资本 200万人民币，由无锡罗伯迈德医疗科技有限公司全资持股。 企业名称上海灵犀慧启医疗科技有限责任公司法定代表人李世英注册资本200万人民币国标行业科学研 究和技术服务业>科技推广和应用服务业>技术推广服务地址上海市闵行区万芳路555号4幢501室企业类 型有限责任公司（自然人投资或控股的法人独资）营业期限2025-8-1至无固定期限登记机关闵行区市场 监督管理局 来源：金融界 ...

Core Insights - The third wave of artificial intelligence (AI) is reshaping the global economy, with China emerging as a significant player due to its vast application scenarios and advancements in chip technology and open-source algorithms [2] - The World Artificial Intelligence Conference (WAIC 2025) highlighted AI's evolution from an "industrial variable" to a "civilizational constant," showcasing its integration into various sectors [2] - Ant Group's digital healthcare division is leveraging AI to enhance user experience and productivity in the medical field, transitioning from traditional internet solutions to AI-driven services [3][10] Company Overview - Ant Group's digital healthcare segment focuses on improving user convenience in medical payments, with 800 million users activating health insurance codes on Alipay [5] - The company offers a comprehensive healthcare channel on Alipay, connecting users with nearly 3,600 public hospitals for services like appointment booking and consultations [5] - In 2023, Ant Group began exploring AI in healthcare, aiming to provide users with an AI health manager to facilitate medical services and assist healthcare professionals [5][10] AI Integration and User Experience - The AI health manager is designed to address user needs by providing professional answers and facilitating service access, such as scheduling appointments and managing health records [6][10] - Ant Group has seen significant user engagement, with nearly 100 million users utilizing the AI health manager since its launch, particularly among middle-aged and elderly users [10] - The AI system is capable of offering proactive health management suggestions based on user data and interactions with healthcare providers [6][10] Challenges and Solutions - The integration of AI in healthcare faces challenges, including establishing standards, ensuring data privacy, and collaborating with medical professionals [7][8] - Ant Group emphasizes the importance of deep collaboration with healthcare institutions and experts to enhance AI capabilities and meet user expectations [7][12] - The company is actively working on developing authoritative evaluation standards for AI models in the medical field, ensuring their effectiveness and compliance [11][12] Future Outlook - The AI-driven transformation in healthcare is expected to significantly enhance productivity and user experience, particularly in underserved regions [10] - Ant Group aims to maintain user trust while navigating challenges related to data privacy and the integration of AI with existing healthcare systems [12] - The company believes that AI will play a crucial role in the future of healthcare, providing substantial social value and warranting long-term investment [10][12]

Core Viewpoint - Zhiyun Health (09955) has demonstrated its strong capabilities in the medical AI sector by successfully entering a key research project focused on generative medical AI models, which is expected to enhance remote decision-making support in healthcare [1] Company Summary - Zhiyun Health's stock rose over 4%, reaching 1.55 HKD with a trading volume of 3.1421 million HKD [1] - The company has been recognized by the Hangzhou Science and Technology Bureau for its project on "Construction of Generative Medical AI Models and Key Technology Research in Remote Decision Support," highlighting its expertise in the medical AI field [1] - The generative medical AI model developed by Zhiyun Health is currently being demonstrated in multiple hospitals across the country, with plans for further expansion in coverage and application depth [1] Industry Summary - The generative medical AI model utilizes IoT perception technology and precise data routing algorithms for medical information transmission, focusing on dynamic data collection for chronic disease patients [1] - The system includes a smart diagnostic assistance system with self-optimizing parameters, enhancing the accuracy and timeliness of remote diagnoses for conditions such as diabetes, cardiovascular diseases, and chronic obstructive pulmonary disease [1] - The overall framework established by the company consists of a closed-loop medical assistance system that integrates data collection, secure transmission, and intelligent decision-making [1]

Group 1 - The Supreme People's Court released 12 typical cases to protect the legitimate rights and interests of private enterprises and entrepreneurs, emphasizing the commitment to fair and impartial justice [1] - The cases highlight the strict distinction between crime and non-crime, as well as between illegal gains and legitimate property, ensuring the protection of private enterprises [1] - The principle of equal protection under the law is fully implemented, with rulings that uphold the rights of private enterprises in contractual disputes [1] Group 2 - The court encourages innovation among researchers and supports private enterprises in international expansion by providing judicial guarantees [2] - The legal system aims to guide and regulate business operations, promoting healthy development and addressing corruption within private enterprises [2] - The exploration of integrated debt resolution for private enterprises aims to stimulate innovation and promote sustainable development [2]

Group 1 - The company, Guoke Hengtai (Beijing) Medical Technology Co., Ltd., held a second extraordinary general meeting in 2025, where the proposal to amend the Articles of Association was approved [1] - The specific details of the amendment to the Articles of Association were disclosed on June 24, 2025, on the Giant Tide Information Network [1] - The company has completed the filing and registration procedures for the amended Articles of Association with the Market Supervision Administration of Beijing Economic and Technological Development Zone [1]

Group 1: US-China Economic Talks - The US and China held economic talks in Stockholm, focusing on trade relations and macroeconomic policies, with a consensus to extend the suspension of certain tariffs for 90 days [1][2] - The Chinese Ministry of Commerce expressed hope for continued dialogue and cooperation to achieve win-win outcomes [1] Group 2: Business Interactions - The US-China business community is actively engaging, with a delegation from the US visiting China, including executives from major companies like Apple and Goldman Sachs [2][3] - 82% of surveyed US companies reported profitability in China for 2024, indicating an improvement compared to the previous two years [3] Group 3: Trade Promotion and Exhibitions - The China Council for the Promotion of International Trade (CCPIT) has facilitated numerous trade exhibitions, with nearly 2,000 Chinese companies participating in events in the US [4][5] - In the first quarter, the US was the top destination for Chinese companies' overseas exhibitions, with a 2.3% increase in exhibition area compared to the previous year [4] Group 4: China-Europe Economic Relations - The 25th China-Europe leaders' meeting resulted in significant agreements on economic cooperation, emphasizing mutual benefits and open markets [7] - China's trade with the EU has grown significantly, with a 3.5% year-on-year increase in imports and exports in the first half of the year, reaching 2.82 trillion yuan [8] Group 5: Trade Data Insights - The integration of supply chains between China and Europe is accelerating, with notable growth in automotive parts exports and imports [9] - China is increasingly importing consumer goods from the EU, with over 60% of certain product categories sourced from the EU [9]

Group 1 - The Global X China Core Technology ETF has officially launched on the Hong Kong Stock Exchange, providing investors with a tool to diversify risks in technology stock investments, focusing on seven high-growth technology sectors and 30 leading Chinese technology companies [1] - The ETF tracks the Future Asset China Technology 30 Index, which includes the top 30 companies in China with potential global competitiveness, with an average market capitalization of $65 billion [1] - The top five sectors represented in the ETF are biotechnology (22%), semiconductors (17%), consumer electronics (17%), electric vehicles (15%), and batteries (9%) [1] Group 2 - China's manufacturing sector has rapidly expanded, now accounting for 30% of global manufacturing, ranking first in the world, with high-tech manufacturing growth outpacing traditional manufacturing [2] - In 2024, China's total R&D expenditure reached 3.6 trillion RMB, a year-on-year increase of 8.3%, maintaining its position as the second-largest globally [2] - Key industries such as semiconductors, renewable energy, and artificial intelligence are national strategic priorities, with domestic companies achieving technological independence and gaining a foothold in global markets [2] Group 3 - The rise of China's technology industry is expected to continue, with upgrades in high-end manufacturing, increased R&D investment, and deeper globalization [3] - The core technology sectors defined by the ETF are crucial for China's self-reliance in high-end technology, including biotechnology, semiconductors, electric vehicles, batteries, medical technology, robotics, consumer electronics, solar energy, and software [3] - The investment strategy of the Global X China Core Technology ETF focuses on 30 leading domestic companies, characterized by broad growth prospects, high R&D spending ratios, and attractive valuation advantages [3]

Core Viewpoint - Northeast Securities maintains an "overweight" rating on Yidu Tech (02158), highlighting significant improvements in market penetration in the medical intelligence sector and record-high gross margins for its self-developed i-series solutions during the fiscal year 2025 [1] Group 1: Market Penetration and Client Base - As of March 31, 2025, the company's big data platform serves 110 top hospitals in China and 44 regulatory agencies, covering over 4,000 hospitals [1] - The Copilot product matrix has been deployed in over 30 tertiary hospitals within three months, creating a complete closed loop of "data governance - intelligent training - scenario implementation," significantly enhancing market penetration in the medical intelligence field [1] - The life sciences segment has served 132 clients, with a revenue retention rate of 87.51% among the top 20 clients, 16 of which are multinational pharmaceutical companies [1] Group 2: Financial Performance and Competitive Edge - The self-developed i-series solutions cover the entire lifecycle of drug development, including clinical development, research design, and commercial risk assessment, with gross margins reaching 33.5%, a historical high, showcasing the company's core competitiveness in pharmaceutical R&D intelligence [1] - The company has been the main operating platform for "Shenzhen Huimin Insurance" for three consecutive years, with 6.09 million insured individuals in 2024, and has operated "Beijing Huimin Insurance" for four years, accumulating over 15 million insured instances [1] - The platform has over 24 million active users, all of whom have completed at least one transaction, indicating strong user reach and market acceptance of health management services, laying a solid foundation for future commercialization [1]

Core Insights - The World Artificial Intelligence Conference (WAIC) in Shanghai highlighted the shift of AI's main battleground from large model parameter competition to practical applications in industries, particularly in healthcare [2][3] - The focus of discussions has moved towards how AI can empower real-world scenarios in diagnosis, payment, and new drug development, aiming for a commercial closed loop [2][3] - The "impossible triangle" in healthcare—high-quality service, broad coverage, and low cost—may be addressed through the maturity of AI and big data capabilities, enabling better healthcare access [2][3] Industry Trends - The integration of AI in healthcare is evolving from isolated breakthroughs to systematic integration, with a focus on digitalization and intelligence [3][4] - The competition has shifted from algorithm performance to data acquisition and compliance, emphasizing partnerships with major hospitals for high-quality data [4][5] - AI's role in healthcare payment systems is becoming crucial, as it is seen as a key to validating AI's business model and creating a value closed loop [4][5] Company Developments - Megxin Health, a Shanghai-based technology platform, is leveraging AI to reconstruct the healthcare payment ecosystem, aiming to integrate the value chain of medicine, pharmaceuticals, and insurance [2][6] - As of June 30, Megxin Health reported serving over 1.6 million patients with a total medical payment amount (GPV) of 39.7 billion yuan, collaborating with over 90 insurance companies and 140 pharmaceutical firms [6][7] - The company is developing an AI central platform named "mind42.ai" to facilitate the integration of medical, pharmaceutical, and insurance ecosystems [6][7] AI Implementation - Megxin Health is focusing on automating the claims process through AI agents, significantly reducing the time required for claims processing from about one day to as little as 10 minutes [13][14] - The AI agent cluster is designed to cover the entire decision-making process in healthcare payments, enhancing efficiency and accuracy [10][11] - The company aims to extend its AI capabilities to more scenarios, including health management for chronic disease patients and patient management for pharmaceutical companies [14][15] Future Outlook - The evolution of AI in healthcare payments is expected to transition from process automation to intelligent risk control and actuarial-driven approaches [15][16] - Megxin Health envisions becoming a participant in setting new industry standards for payment processes and claims regulations, leveraging technology to optimize healthcare resource allocation [15][16] - The integration of AI in insurance pricing and claims decisions raises concerns about data transparency and algorithmic bias, prompting Megxin Health to implement rigorous data quality and decision-making transparency measures [16][17]

Core Insights - The 11th International Minimally Invasive Urology Conference was held in Bangkok, marking a significant collaboration between Thailand and China in the healthcare sector [1][2] - A successful remote surgery was conducted using a robotic system, demonstrating the reliability and safety of robotic-assisted remote surgical operations [2][5] Group 1: Remote Surgery Implementation - The remote surgery involved a kidney operation on an experimental animal located 2800 kilometers away in Shanghai, showcasing the precision and stability of the robotic system [2] - This event is a milestone for Thailand in advancing international collaboration in robotic surgery, remote healthcare, and surgical training [2][6] Group 2: Technological Advancements - Robotic-assisted remote surgery is recognized as a crucial development in modern medical technology, allowing for high-complexity minimally invasive surgeries without direct patient contact [5] - The integration of new communication technologies with surgical robotics provides a pathway to address the imbalance in healthcare resource distribution, potentially improving access to quality medical services [5][6] Group 3: Future Directions - The Thai Ministry of Public Health aims to continue promoting the introduction and implementation of advanced medical technologies to enhance the capabilities of regional hospitals and improve healthcare quality and accessibility [6]